BioSight
Companies
Phathom Pharmaceuticals, Inc. logo

PHAT

NASDAQFLORHAM PARK, NJ
Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company focused on gastrointestinal diseases with approved products VOQUEZNA, VOQUEZNA DUAL PAK, and VOQUEZNA TRIPLE PAK, which contain vonoprazan, an oral small molecule potassium-competitive acid blocker. The company commercializes these products for the treatment of erosive gastroesophageal reflux disease and Helicobacter pylori infection in the United States.

Price history not yet available for PHAT.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar